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CFS by RT modality (p = 0.62, p = 0.87, p = 0.76) or CT regimen 
(p = 0.94, p = 0.78, p = 0.90). 
Conclusions: IMRT and HT differ with respect to dose 
homogeneity and normal-tissue sparing. Acute toxicity was 
significantly increased in patients receiving MMC2 compared to 
MMC1. However, there were no differences in outcome based on 
either RT modality or chemotherapeutic regimen between these 
cohorts. 
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Purpose: Image-guided, intensity-modulated radiation therapy 
(IG-IMRT) allows accurate, conformal treatment of the prostate 
bed post-prostatectomy. However, a large planning target 
volume (PTV) is still required to address deformations due to 
variations in rectum and bladder filling. Adaptive radiation 
therapy is a potential solution that has not been explored in this 
setting. We present the results of a feasibility study of ART for 
post-prostatectomy prostate cancer. 
Material and Methods: Twenty-one patients were initially 
planned and treated with IG-IMRT according to our institutional 
standard. The original clinical target volume, plus the CTV that 
was recontoured on cone-beam CT (CBCT) images from the first 
four fractions and used to create an adapted PTV. A new plan 
using the adapted PTV was implemented on fraction 7 and used 
for the remaining 27 fractions. The primary study endpoint was 
improvement in dosimetric plan quality. 
Results: All patients were successfully recontoured and 
replanned within the allotted 3 day period, requiring a mean of 
1.9 days (0.4 days standard deviation). The mean adapted PTV 
volume was 19% (60 cc) smaller than the standard PTV (p < 
0.001), and smaller than standard PTV for 20 of 21 patients. 
Reconstruction of the dose delivered on 102 recontoured weekly 
CBCT following adaptation shows the mean CTV coverage is 
similar although slightly lower in ART plans (mean CTV D99 94% 
[1%]) compared to if the unadapted standard plans had been 
continued (96% [1%]) (p < 0.001). Reconstructed small bowel dose 
demonstrated fewer fractions of the ART plan with small bowel 
exceeding 75% of the prescription dose (11% ART fractions versus 
18% standard, p < 0.01). 
Conclusions: ART for post-prostatectomy prostate cancer is 
feasible and safe, facilitates PTV volume reduction while 
maintaining reasonable CTV coverage, and can reduce the dose 
to adjacent normal tissues. 
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Purpose: Metastatic renal cell carcinoma (mRCC) represents one 
of the few end-stage malignancies where aggressive treatment 
to the primary tumour (i.e. cytoreductive nephrectomy) is 
associated with a survival benefit. Criteria published by (Heng et 
al. 2009) have assisted in the risk-stratification of patients who 
may benefit most from this, but many are not surgical candidates 
due to medical inoperability or unresectable disease. We 
hypothesized that SABR could serve as a safe alternative 
modality for such patients. Our study objectives were to report 
on technical considerations, toxicity, and outcomes of our 
institutional experience with SABR for large renal tumours. 
Methods and Materials: In this research ethics board approved 
study, a retrospective review of patient databases was 
conducted to identify patients with RCC (presumed or biopsy-
confirmed) who underwent SABR at our institution between 
January 2008 and June 2015. Clinical and dosimetric data were 
abstracted from electronic and paper records. Toxicity was 
quantified using the CTCAE v4.0 and the RECIST classification 
was used to evaluate radiographic response. Median overall 
survival and follow up were calculated using the Kaplan-Meier 
and reverse Kaplan-Meier methods, respectively. 
Results: We identified 11 patients of median age 79 (range 61-
87), the majority (n = 9) with Stage III-IV disease. Patients were 
classified as poor (n = 5) or intermediate (n = 4) risk based on the 
model by Heng et al. SABR was directed to the tumour alone (n 
= 7) or the whole kidney (n = 4). Median tumour size, GTV, and 
PTV were 9.5 cm (range: 7.5-24.4), 482.6 cm3 (range: 185.7 – 
4617.8), and 819.3 cm3 (range: 313.4 – 5704.3), respectively. 
SABR was delivered in five fractions to a dose of 25 (n = 6), 30 (n 
= 3), 35 (n = 1), or 40 Gy (n = 1). Favourable coverage of 
treatment volumes and largely acceptable doses to organs at risk 
were achieved via IMRT (n = 6), Helical Tomotherapy (n = 3), or 
VMAT (n = 2). Median follow up was 12.9 months (95% confidence 
interval [CI]: 1.3 – 56.1). Five cases of CTCAE Grade 1 toxicities 
were reported. Grade 2 diarrhea and probable Grade 3 nausea 
were observed in one patient with the largest tumour treated in 
the study. In patients with follow up imaging (n = 7), SABR 
resulted in stable disease (n = 5), partial response (n = 1), or 
progressive disease (n = 1). Median overall survival was 20.4 
months (95% CI: 4.24 – N/A) 
Conclusions: SABR can be delivered safely and with minimal 
toxicity, as demonstrated in this small retrospective cohort of 
patients with large primary renal tumours. A Phase I study at our 
institution is currently underway to prospectively determine 
maximum tolerable and optimal dosing in this setting 
(NCT02264548). 
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Purpose: Low baseline testosterone level is a known adverse 
prognostic factor in patients treated with prostatectomy and a 
positive predictive factor in patients treated for metastases or 
recurrences. Little is known about its importance in radiotherapy 
for localized prostate cancer. 
Methods and Materials: Patients treated at our institution in 
prospective Phase 2 or 3 clinical trials and who had a baseline 
total testosterone level available before initiation of any 
treatment were selected from our institutional database. All 
patients received between 70-79.2 Gy in 1.8-2 Gy per fraction or 
a biological equivalent dose in hypofractionated protocols. A 
total testosterone (TT) level of < 10.4 nmol/L (< 300 ng/dL) was 
chosen as a cut-off, this being often used to define low TT levels. 
Results: A total of 360 patients were identified. Of these, 71% 
had D’Amico low- or intermediate-risk cancers, the remainder 
having high-risk cancers. Fifty-eight percent were > 70 years old 
and 29% had a BMI > 30 kg/m2 (BMI data was available in 76% of 
the patients). Median follow up was 67 months (IQR 40-90 
months). Baseline TT level was < 10.4 nmol/L in 58% of patients. 
Sixty-four patients (18%) experienced biochemical recurrence 
(BCR). Median time to BCR was 57 months (range 5-112 months). 
Fifty-five patients died at a median of 64 months after treatment 
(IQR 36-80 months). Testosterone as a continuous variable was 
not correlated to age (p = 0.27) and only weakly inversely 
correlated to BMI (r=-0.16, p = 0.009). On univariate analysis, 
patients with a TT< 10.4 nmol/L value had significantly lower 
rate of BCR (p = 0.044). This effect was maintained on 
